Intellia Therapeutics Inc (NTLA) Company Profile & Statistics

Intellia Therapeutics Inc
NTLA
(Nasdaq - US)
Closed
13.79
+0.67 (+5.11%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
13.26
High
14.38
Low
13.26

About Intellia Therapeutics Inc

CEO

John M. Leonard

Headquarters

40 erie street, suite 130

cambridge, ma 02139, united states

Auditor

Deloitte & Touche LLP

Employees

526

Share Holders

Website

www.intelliatx.com

Industry

biotechnology

Sector

health technology

Company Overview

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.?

Intellia Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	1.40B
Enterprise Value	1.28B
Enterprise Value/EBITDA (ttm)	-2.43
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.49
Price to Sales (ttm)	27.80
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	730.17%
Return on Equity (ttm)	-49.34%
Return on Invested Capital (ttm)	-52.19%
Return on Assets (ttm)	-40.27%

Income Statement

Revenue (ttm)	43.09M
Revenue Per Share (ttm)	0.42
Gross Profit (ttm)	43.09M
EBITDA (ttm)³	-527.52M
Net Income Avi to Common (ttm)	-522.28M
Diluted EPS (ttm)	-5.44

Share Statistics

Beta (5Y Monthly)	1.81
52-Week Change	-54.46%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	101.85M
Dividend Yield	0.00%
Float ⁴	98.59M
% Held by Insiders	3.20%
% Held by Institutions	88.77%

Balance Sheet

Total Cash (mrq)	658.11M
Total Cash Per Share (mrq)	6.46
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	6.73%
Quick Ratio (mrq)	6.73%
Book Value Per Share (mrq)	9.46

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.61
Free Cash Flow (ytd)	-268.48M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Intellia Therapeutics Inc

Trade With A Regulated Broker